Ophthalmological composition of the type which undergoes liquid-gel phase transition

• US 4,861,760 A
• Filed: 09/25/1986
• Issued: 08/29/1989
• Est. Priority Date: 10/03/1985
• Status: Expired due to Term

• Current Assignee: Chibret International, SA
• Original Assignee: Merck & Co., Inc.
• Inventors: Friteyre, Marie-Claire, Mazuel, Claude
• Primary Examiner(s): Griffin, Ronald W.
• Assistant Examiner(s): Carson, Nancy S.
• Application Number:
  US06/911,606
• Time in Patent Office: 1,069 Days
• Field of Search: 514/54, 514/944, 514/912, 514/913, 514/915, 514/954, 536/123, 536/114, 536/1.1
• US Class Current: 514/54
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: C12P 19/04 Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

The present invention relates to a pharmaceutical composition intended for contacting with a physiological liquid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said physiological liquid.

Claims

1. A liquid aqueous ophthalmological composition comprising 0.1 to 2% by weight of gellan gum which on administration to the eye changes from a liquid to a gel as a result of the ionic strength of the lacrimal fluid.

2. The composition of claim 2 which additionally comprises about 0.001% to 5% by weight of an ophthalmic pharmaceutically-active substance.

3. The composition of claim 2 wherein the pharmaceutically-active substance is selected from the group consisting of an antibacterial substance and an anti-glaucoma drug.

4. The composition of claim 3 wherein the antibacterial substance is norfloxacin and the antiglaucoma drug is timolol maleate or a carbonic anhydrase inhibitor.

5. The composition of claim 1 wherein the gellan gum is Gelrite.

6. The composition of claim 5 which additionally comprises about 0.001% to 5% by weight of an ophthalmic pharmaceutically-active substance.

7. The composition of claim 6 wherein the pharmaceutically-active substance is selected from the group consisting of an antibacterial substance and an antiglaucoma drug.

8. The composition of claim 7 wherein the antibacterial substance is norfloxacin and the antiglaucoma drug is selected from the group consisting of timolol maleate and a carbonic anhydrase inhibitor.